Literature DB >> 30083835

Incidence and Distribution of Lobe-Specific Mediastinal Lymph Node Metastasis in Non-small Cell Lung Cancer: Data from 4511 Resected Cases.

Run-Bin Liang1,2,3, Jie Yang1,2,3, Tai-Shan Zeng4, Hao Long1,2,3, Jian-Hua Fu1,2,3, Lan-Jun Zhang1,2,3, Peng Lin1,2,3, Xin Wang1,2,3, Tie-Hua Rong1,2,3, Xue Hou5,6,7, Hao-Xian Yang8,9,10.   

Abstract

OBJECTIVE: We aimed to investigate the incidence and distribution of mediastinal lymph node metastases (MLNM) in operable non-small cell lung cancer (NSCLC) with the purpose of guiding mediastinal lymph node dissection (MLND).
METHODS: A total of 4511 NSCLC patients who underwent resection between January 2001 and December 2014 were included. These patients were preoperatively untreated and grouped according to the primary tumor lobes. The incidence and distribution of pathologic MLNM were compared among groups, and multivariate analysis was conducted to find the independent factors impacting MLNM.
RESULTS: Lymph node involvement was observed in 1784 patients (39.5%). A total of 628 cases (13.9%) were N1-positive only, 752 cases (16.7%) were both N1- and N2-positive, and 404 cases (9.0%) were N2-positive only. The most common sites of mediastinal metastasis for different primary tumor lobes were the right upper lobe, station 4R (21.5%, 192/893); right middle lobe, station 7 (21.1%, 69/327); right lower lobe, station 7 (24.1%, 212/878); left upper lobe, station 5 (22.2%, 224/1008); and left lower lobe, station 7 (21.7%, 136/628). However, when only N2 cases were considered, each mediastinal lymph node zone can be involved with metastasis to a high proportion (> 5%). Multivariable analyses showed that poor cell differentiation, adenocarcinoma, larger tumor size, central type, and younger age were independent factors favoring MLNM.
CONCLUSIONS: Different primary tumor locations have a different propensity to be sites of MLNM; however, once MLNM occurs, each zone can be involved and should not be neglected. Systematic MLND is the preferred procedure for operable NSCLC.

Entities:  

Mesh:

Year:  2018        PMID: 30083835     DOI: 10.1245/s10434-018-6394-9

Source DB:  PubMed          Journal:  Ann Surg Oncol        ISSN: 1068-9265            Impact factor:   5.344


  10 in total

1.  Prognostic significance of 4R lymph node dissection in patients with right primary non-small cell lung cancer.

Authors:  Di Zhou; Dongsheng Yue; Zhenfa Zhang; Pengfei Tian; Yingnan Feng; Zuo Liu; Bin Zhang; Meng Wang; Xiaoliang Zhao; Changli Wang
Journal:  World J Surg Oncol       Date:  2022-07-01       Impact factor: 3.253

2.  Nodal Involvement Pattern in Clinical Stage IA Non-Small Cell Lung Cancer According to Tumor Location.

Authors:  Shushi Meng; Ganwei Liu; Shaodong Wang; Fan Yang; Jun Wang
Journal:  Cancer Manag Res       Date:  2020-08-26       Impact factor: 3.989

3.  Who are the real high-risk patients with pathological T2N0M0 non-small-cell lung cancer that can benefit from adjuvant chemotherapy?

Authors:  X Hou; M-Z Yang; J-B Li; Z-H Tan; H Long; J-H Fu; L-J Zhang; P Lin; H-X Yang
Journal:  ESMO Open       Date:  2022-06-07

4.  Spanish Lung Cancer Group SCAT trial: surgical audit to lymph node assessment based on IASLC recommendations.

Authors:  José Ramón Jarabo Sarceda; Sergio Bolufer Nadal; Roberto Mongil Poce; Pedro López de Castro; Ramón Moreno Balsalobre; Juan Carlos Peñalver Cuesta; Raul Embún Flor; Joaquín Pac Ferrer; Francisco Javier Algar Algar; Antonio Pablo Gámez García; Marcelo F Jiménez; Jesús Gabriel Sales-Badía; Eva Pereira; Bartomeu Massuti; Mariano Provencio; Florentino Hernando Trancho
Journal:  Transl Lung Cancer Res       Date:  2021-04

5.  A Comprehensive Nomogram Combining CT Imaging with Clinical Features for Prediction of Lymph Node Metastasis in Stage I-IIIB Non-small Cell Lung Cancer.

Authors:  Xingxing Zheng; Jingjing Shao; Linli Zhou; Li Wang; Yaqiong Ge; Gaoren Wang; Feng Feng
Journal:  Ther Innov Regul Sci       Date:  2021-10-26       Impact factor: 1.778

6.  Numbers and Stations: Impact of Examined Lymph Node on Precise Staging and Survival of Radiologically Pure-Solid NSCLC: A Multi-Institutional Study.

Authors:  Donglai Chen; Yiming Mao; Junmiao Wen; Jian Shu; Fei Ye; Yunlang She; Qifeng Ding; Li Shi; Tao Xue; Min Fan; Yongbing Chen; Chang Chen
Journal:  JTO Clin Res Rep       Date:  2020-03-23

7.  Station 3A lymph node dissection does not improve long-term survival in right-side operable non-small-cell lung cancer patients: A propensity score matching study.

Authors:  Mu-Zi Yang; Zi-Hui Tan; Ji-Bin Li; Hao Long; Jian-Hua Fu; Lan-Jun Zhang; Peng Lin; Xue Hou; Hao-Xian Yang
Journal:  Thorac Cancer       Date:  2022-06-15       Impact factor: 3.223

8.  Mediastinal lymph node evaluation, especially at station 4L, in left upper lobe lung cancer.

Authors:  Jun Hanaoka; Makoto Yoden; Keigo Okamoto; Ryosuke Kaku; Yasuhiko Ohshio
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

9.  Effect of 3A lymph node resection on survival in patients with right-sided NSCLC: a retrospective, multicentre, propensity-score matching study.

Authors:  Marcin M Cackowski; Marcin Zbytniewski; Grzegorz M Gryszko; Michał Dziedzic; Katarzyna Woźnica; Tadeusz M Orłowski; Dariusz A Dziedzic
Journal:  J Thorac Dis       Date:  2022-09       Impact factor: 3.005

10.  Correlation between tumor location and survival in stage I lung adenocarcinoma and squamous cell carcinoma: a SEER-based study.

Authors:  Junjie Hu; Mengfan Qi; Xinsheng Zhu; Yan Chen; Jie Dai; Jing Zhang; Gening Jiang; Zhonghong Zhang; Peng Zhang
Journal:  J Cancer       Date:  2021-06-22       Impact factor: 4.207

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.